Back

Co-stimulatory immune checkpoint signalling in cardiac fibrosis: distinct pathological outcomes of ICOS and ICOSL blockade

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Cardiac fibrosis and remodelling Fibrosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Zsombor I Hegedus

Semmelweis University, Budapest (Hungary)

3 More presentations in this session

Presentation thumbnail
DDX21-mediated epigenetic remodeling drives cardiac fibroblast activation and fibrosis post-myocardial infarction by stabilizing SLC16A3 expression
Doctor Z. Tao (Nanjing, CN)
Abstract
Presentation thumbnail
Moderate coffee/caffeine intake attenuates cardiac remodelling through fibroblast-selective NCX/NFATc3 signalling
Associate Professor Y. Saliba (Beirut, LB)
Abstract
Presentation thumbnail
Teaching old drugs new tricks: high-throughput drug screening identifies a novel, therapeutic combination for the potential treatment of atrial fibrillation-associated cardiac fibrosis
Mr A. Johnston (Oxford, GB)
Abstract

Access the full session

Session thumbnail
Cardiac fibrosis and remodelling

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Myocardial expression of immune checkpoint molecules in patients with advanced heart failure
20 June 2025
thumbnail
Congress Presentation
Mechanosensitive molecular mechanisms of myocardial fibrosis in living myocardial slices
29 June 2021
thumbnail
Congress Presentation
Subclinical cardiac organ damage in patients with moderate to severe psoriasis treated with infliximab
27 August 2021
thumbnail
Congress Presentation
Loss of smooth muscle SDF-1/CXCL12 leads to cardiac hypertrophy and aortic valve stenosis
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources